As of 2024-10-13, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is (17.70) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.43 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is -338.3%.
The range of the Relative Valuation is (16.55) - (18.07) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.3x - 38.1x | 25.9x |
| Forward P/E multiples | 23.5x - 25.6x | 24.3x |
| Fair Price | (16.55) - (18.07) | (17.70) |
| Upside | -322.7% - -343.2% | -338.3% |
| Date | P/E |
| 2024-10-11 | -10.53 |
| 2024-10-10 | -10.09 |
| 2024-10-09 | -10.28 |
| 2024-10-08 | -10.21 |
| 2024-10-07 | -10.55 |
| 2024-10-04 | -10.75 |
| 2024-10-03 | -10.52 |
| 2024-10-02 | -10.46 |
| 2024-10-01 | -10.46 |
| 2024-09-30 | -10.77 |
| 2024-09-27 | -10.80 |
| 2024-09-26 | -10.75 |
| 2024-09-25 | -10.70 |
| 2024-09-24 | -10.82 |
| 2024-09-23 | -11.04 |
| 2024-09-20 | -11.50 |
| 2024-09-19 | -11.55 |
| 2024-09-18 | -11.28 |
| 2024-09-17 | -11.23 |
| 2024-09-16 | -11.21 |
| 2024-09-13 | -11.23 |
| 2024-09-12 | -10.99 |
| 2024-09-11 | -10.96 |
| 2024-09-10 | -10.94 |
| 2024-09-09 | -10.87 |
| 2024-09-06 | -11.31 |
| 2024-09-05 | -11.53 |
| 2024-09-04 | -11.74 |
| 2024-09-03 | -11.70 |
| 2024-08-30 | -12.32 |
| 2024-08-29 | -12.23 |
| 2024-08-28 | -12.12 |
| 2024-08-27 | -11.67 |
| 2024-08-26 | -11.67 |
| 2024-08-23 | -11.48 |
| 2024-08-22 | -11.24 |
| 2024-08-21 | -11.36 |
| 2024-08-20 | -11.09 |
| 2024-08-19 | -11.14 |
| 2024-08-16 | -10.83 |
| 2024-08-15 | -10.82 |
| 2024-08-14 | -11.14 |
| 2024-08-13 | -11.19 |
| 2024-08-12 | -10.96 |
| 2024-08-09 | -10.82 |
| 2024-08-08 | -11.30 |
| 2024-08-07 | -10.55 |
| 2024-08-06 | -11.16 |
| 2024-08-05 | -10.65 |
| 2024-08-02 | -9.95 |